On Monday, James P. Allison, PhD, a Fellow of the AACR Academy and a past member of the AACR’s Board of Directors, won the 2018 Nobel Prize in Physiology or Medicine for his pioneering work in cancer immunotherapy.Read More
As a monthly feature on this blog, we spotlight the 10 articles selected by our editors from each journal issue published by the American Association of Cancer Research (AACR). These journals feature original articles spanning the continuum of cancer research, from basic science discoveries to patient care.Read More
In the midst of the dog days of summer, the U.S. Food and Drug Administration (FDA) has provided good news for the cancer community: It has approved two new anticancer therapeutics for the treatment of four rare types of cancer.Read More
Treatment with checkpoint inhibitors is often billed as gentler than chemotherapy—and it is true that immunotherapy doesn’t come with the same acute side effects, such as hair loss, characteristic of many chemotherapy drugs. But checkpoint inhibitors are not without side effects.
In a story published in the summer 2018 issue of Cancer Today, digital editor Kate Yandell discusses what is known about checkpoint inhibitor side effects and how to spot and treat them.Read More
During the early part of summer 2018, the U.S. Food and Drug Administration (FDA) has approved several new anticancer therapeutics and expanded the use of some previously approved anticancer therapeutics to include new types of cancer.Read More
This week marks the fourth anniversary of Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR). As outlined in the welcome post from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), the blog was launched to increase the spread of new knowledge about cancer.
Over these four years, our blog posts have disseminated information about advances across the breadth of cancer research and the clinical cancer care continuum. One area in which advances have occurred at a particularly rapid pace is immunotherapy.Read More
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.Read More
A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …Read More
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form …Read More
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …Read More